Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Oova grabs another $10.3M, unveils membership model for at-home fertility testing

From TechCrunch

By Christine Hall

June 12, 2023

Oova grabs another $10.3M, unveils membership model for at-home fertility testing

Oova grabs another $10.3M, unveils membership model for at-home fertility testing

One in six people are expected to be affected by infertility at some point in their lives, and with the cost of procedures, like in vitro fertilization, costing tens of thousands of dollars for each procedure, more people seek better ways to know their reproductive health.

There are a number of startups tackling this issue, for example, Generation Prime, Flo, Future Family, Mave and Mate Fertility, which all received funding within the past few years.

Oova, a women’s health and fertility startup working in the fertility tracking segment of the market, is the latest to get additional venture-backed funding, raising $10.3 million in Series A funding for its at-home approach to translating a woman’s fertility.

It is also launching the Oova Membership. Priced at $99 per month, the membership includes The Oova Kit (a $159 value) and offers features, including personalized support via the Oova Provider network of healthcare professionals and hormone experts and access to a community of people going through similar fertility journeys.

Oova raises $1.2M to develop a better at-home kit for detecting a woman’s best time to conceive

Oova was previously profiled in 2021 when founder and CEO Amy Divaraniya, Ph.D. officially launched its at-home urine test, called Oova Kit, with $1.2 million in seed funding. The test comes with 15 days of testing strips and measures the luteinizing hormone and progesterone to provide advanced personalized analytics and real-time action plans so a woman can know her most fertile days and confirm ovulation.

Oova, Oova Kit, at-home fertility test

Oova’s Oova Kit, an at-home fertility test. (Image Credit: Red Antler)

It is FDA registered, and the company touts it is the “only product that allows its users to sync and share results with their doctor in real time.” Divaraniya told TechCrunch that talk within the fertility industry, especially following the overturning of Roe v. Wade in 2022, shifted to data security, and unlike other period and fertility tracking companies, Oova was always HIPAA compliant and invested in secure connections with its clinic partners.

Divaraniya was mum about the company’s growth over the past year, but did say Oova is now working with over 100 clinics, up from 75 at the launch in 2021. In addition, the company has trained its model on over 10,000 cycles monitored through the platform.

“We’ve also seen a massive increase in the adoption across both consumer and clinical channels,” Divaraniya said. “Because of the adoption, it led to one of the most powerful datasets in the industry. This is a dream of information to work with. Not only do we have daily hormone measurements across tens of thousands of cycles, but we also have treatment data. We’ve been able to train our algorithms on actual hormone information across thousands of women, and then even look at intrapersonal data to understand the nuances between cycles for a single woman, leading to a very personalized experience for our users.”

Meanwhile, Spero Ventures led the new round and was joined by US Fertility, Virgin Group, Jefferson Health, Connecticut Innovations, Hannah Bronfman and Spanx founder Sara Blakely. In total, the company raised $11.5 million.

“Oova has revolutionized the way we understand our hormonal health,” said Sara Eshelman, partner at Spero Ventures, in a written statement. “By making clinical-grade hormone monitoring convenient and cost-effective for daily use, Oova is empowering its users to understand their cycles, improve fertility outcomes and manage their symptoms.”

Divaraniya said Oova went after a new funding round when its technology reached some heavy adoption and the company received feedback from physicians asking for Oova to test additional hormones.

Patients are also using Oova’s technology for use cases that it wasn’t initially designed for, like the early part of pregnancy and postpartum, but are finding value in the data. In addition, the company is eyeing all other phases of a women’s health.

“We started off with fertility because it’s a place that I’m very passionate about, but what is also very clear is that all the different phases of a woman’s life are dictated by hormones,” she said. “If you can understand the different patterns that happen in classic urban spaces, you can actually start adjusting those.”

8 investors discuss what’s ahead for reproductive health startups in a post-Roe world

Oova grabs another $10.3M, unveils membership model for at-home fertility testing by Christine Hall originally published on TechCrunch

Most Recent

Travis Kalanick’s robotics company raises $1.7B, led by a16z

Travis Kalanick’s robotics company raises $1.7B, led by a16z

Uber is also investing in Travis Kalanick's company Atoms, which has made gauzy claims about using industrial AI to modernize the world.

Jul 22, 2026

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

As Chinese AI models grow in capability and popularity among U.S. companies, the arguing over what should be done about them has reached a fever pitch.

Jul 22, 2026

Cascade raises $3.5M to help construction firms find and win projects

Cascade raises $3.5M to help construction firms find and win projects

a16z Speedrun, Ada Ventures, and Snowball VC have invested in Cascade's $3.5 million seed round.

Jul 22, 2026

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

We’ve compiled an overview of some of the top alternative browsers available today aiming to challenge Chrome and Safari.

Jul 22, 2026

Similar Posts

Prickly Pear Health will showcase how it’s helping women’s brain health at TechCrunch Disrupt 2025

Prickly Pear Health will showcase how it’s helping women’s brain health at TechCrunch Disrupt 2025

Prickly Pear Health provides medical support for women’s brain health, a voice-first, AI-powered companion that helps women in their 30s to 50s navigate the hormonal changes that affect brain health.

Oct 1, 2025

Inito, a startup that helps women quickly track fertility hormones at home, raises $6M

Inito, a startup that helps women quickly track fertility hormones at home, raises $6M

Inito, a YC alum that helps women track fertility hormones quickly at home, has raised $6 million in Series A funding led by Fireside Ventures. The startup’s fertility monitor and kit is designed to give users easy-to-read fertility diagnostic results directly on their phone in just 10 minutes. The Bengaluru, India-based startup was founded in […]

Nov 15, 2023

Fertifa enables companies to offer fertility and reproductive health benefits

Fertifa enables companies to offer fertility and reproductive health benefits

The number of workplaces offering fertility and reproductive healthcare benefits are on the rise. Doing so can help companies become more competitive employers and bolster diversity, equity and inclusion efforts, for example by attracting more women and LGBTQ+ people. Based in London, Fertifa wants to enable more companies in Europe to offer reproductive benefits to […]

Jun 30, 2023

Mira is helping fill the hormone knowledge gap for women and the medical industry

Mira is helping fill the hormone knowledge gap for women and the medical industry

Hormones play a massive role in when and how easily women can get pregnant, but research and resources in this area are lacking. Mira is looking to change that. Mira is an at-home, palm-sized hormone testing device women use to test their urine for their hormone levels. Mira’s corresponding app deciphers their results and spots patterns which help women better plan for the right time to try to get pregnant or know when it’s time to bring up potential issues with their doctor. Sylvia Kang, the c

Sep 10, 2024

Most Recent

Travis Kalanick’s robotics company raises $1.7B, led by a16z

Travis Kalanick’s robotics company raises $1.7B, led by a16z

Uber is also investing in Travis Kalanick's company Atoms, which has made gauzy claims about using industrial AI to modernize the world.

Jul 22, 2026

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

As Chinese AI models grow in capability and popularity among U.S. companies, the arguing over what should be done about them has reached a fever pitch.

Jul 22, 2026

Cascade raises $3.5M to help construction firms find and win projects

Cascade raises $3.5M to help construction firms find and win projects

a16z Speedrun, Ada Ventures, and Snowball VC have invested in Cascade's $3.5 million seed round.

Jul 22, 2026

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

We’ve compiled an overview of some of the top alternative browsers available today aiming to challenge Chrome and Safari.

Jul 22, 2026

Similar Posts

Prickly Pear Health will showcase how it’s helping women’s brain health at TechCrunch Disrupt 2025

Prickly Pear Health will showcase how it’s helping women’s brain health at TechCrunch Disrupt 2025

Prickly Pear Health provides medical support for women’s brain health, a voice-first, AI-powered companion that helps women in their 30s to 50s navigate the hormonal changes that affect brain health.

Oct 1, 2025

Inito, a startup that helps women quickly track fertility hormones at home, raises $6M

Inito, a startup that helps women quickly track fertility hormones at home, raises $6M

Inito, a YC alum that helps women track fertility hormones quickly at home, has raised $6 million in Series A funding led by Fireside Ventures. The startup’s fertility monitor and kit is designed to give users easy-to-read fertility diagnostic results directly on their phone in just 10 minutes. The Bengaluru, India-based startup was founded in […]

Nov 15, 2023

Fertifa enables companies to offer fertility and reproductive health benefits

Fertifa enables companies to offer fertility and reproductive health benefits

The number of workplaces offering fertility and reproductive healthcare benefits are on the rise. Doing so can help companies become more competitive employers and bolster diversity, equity and inclusion efforts, for example by attracting more women and LGBTQ+ people. Based in London, Fertifa wants to enable more companies in Europe to offer reproductive benefits to […]

Jun 30, 2023

Mira is helping fill the hormone knowledge gap for women and the medical industry

Mira is helping fill the hormone knowledge gap for women and the medical industry

Hormones play a massive role in when and how easily women can get pregnant, but research and resources in this area are lacking. Mira is looking to change that. Mira is an at-home, palm-sized hormone testing device women use to test their urine for their hormone levels. Mira’s corresponding app deciphers their results and spots patterns which help women better plan for the right time to try to get pregnant or know when it’s time to bring up potential issues with their doctor. Sylvia Kang, the c

Sep 10, 2024